Endogenous Toxins: Targets for Disease Treatment and Prevention, 2 Volume Set
Clearly divided into four parts, the first systematically covers important toxic molecule species, including metabolic intermediates and reactive oxygen species. The second discusses the role of genetically determined metabolic malfunctions, such as galactosemia, hyperlipidemia, porphyria, hemochromatosis and related conditions, while part three looks at acquired and chronic diseases caused or exacerbated by endogenous toxins, such as hepatic injury, asthma, rheumatism, colorectal cancer, reperfusion diseases, neurodegneration and aging. The final part reviews currents strategies to control and minimize the effect of endogenous toxins, either by nutritional or pharmacological interventions.
With its complete coverage integrating molecular and systemic aspects from the biochemical basis to human disease conditions, this comprehensive reference will appeal to a broad target group of toxicologists, biochemists, nutrition specialists and physicians.
1: Endogenous DNA damage
2: Modification of cysteine residues in protein
3: Endogenous macromolecule radicals
4: Alcohol-derived bioadducts
5: Iron from meat produces endogenous pro-carcinogen peroxides
6: Short chain sugars as endogenous toxins
7: Fructose-derived endogenous toxins
8: Cytotoxicity and oxidative stress induced by the glyceraldehyde-related Maillard reaction products
9: Estrogens as Endogenous Toxins
10: Reactive oxygen species (ROS), hypohalites (HOCI), and reactive nitrogen species (NOS)
PART B: GENETICS, ENDOGENOUS TOXINS ASSOCIATED WITH INBORN ERRORS OF METABOLISM
11: Oxalate and primary hyperoxaluria
12: Pathophysiology of endogenous toxins and their relation to in-born errors of metabolism and drug mediated toxicities
13: Mechanisms of toxicity in fatty acid oxidation disorders
14: Homocysteine as an endogenous toxin in cardiovascular disease
15: Uric acid alterations in cardiometabolic disorders and gout
16: Genetic defects in iron and copper trafficking
17: Polyglutamine neuropathies: Animal models to molecular mechanisms
PART C: EXAMPLES OF ENDOGENOUS TOXINS ASSOCIATED WITH ACQUIRED DISEASES OR ANIMAL DISEASE MODELS
18: Alcohol-induced hepatic injury
19: Ethanol-induced endotoxemia and tissue injury
20: Gut microbiota, diet, endotoxemia and disease
21: Nutrient derived endogenous toxins in the pathogenesis of Type 2 diabetes at the beta cell level
22: Endogenous toxins and susceptibility or resistance to diabetes complications
23: Serum advanced glycation end products associated with NASH and other liver diseases
24: Oxidative stress in the pathogenesis of hepatitis C
25: Oxidised low density lipoprotein cytotoxicity and vascular disease
26: Oxidative stress in breast cancer carcinogenesis
27: Lifestyle, endogenous toxins and colorectal cancer risk
28: Dopamine-derived neurotoxins and Parkinson's disease
29: Dopamine catabolism and Parkinson's disease: Role of a reactive aldehyde intermediate
30: Tetrahydropapaveroline, an endogenous dicatechol isoquinoline
31: Chemically-induced autoimmunity
32: Endogenous toxins associated with life expectancy and aging
PART D: THERAPEUTICS PROPOSED FOR DECREASING ENDOGENOUS TOXINS
33: Therapeutic potentials for decreasing the endogenous toxin homocysteine: Clinical trials
34: Prevention of oxidative stress-induced disease by natural dietary compounds: The mechanism of actions
35: Genotoxicity of endogenous estrogens
36: Design of nutritional interventions for control of cellular oxidation
William R. Bruce is Professor emeritus at the Departments of Medical Biophysics and Nutritional Sciences at the University of Toronto (Canada). He is a fellow of the Royal Society of Canada and a former director of the American Association for Cancer Research. In 1997 he received the H. O. Warwick Prize of the National Cancer Institute of Canada for his contributions to cancer prevention.
Wiley-VCH is pleased to announce the timely publication of a unique new reference on a hitherto neglected topic. Endogenous Toxins: Targets for Disease Treatment and Prevention is the only comprehensive handbook on a rising concern for our aging and progressively overfed world population.
Contrary to common belief, a great many human diseases are not dependent on outside factors (such as pathogens or hazardous chemicals), but are caused by molecules generated within the body. These so-called endogenous toxins come in many varieties and their presence can be due to malnutrition, an imbalanced diet, excessive eating or drinking, or genetic defects. There is a growing awareness of these "silent toxins" which are ever-present and largely determine our risk of developing chronic diseases such as diabetes, metabolic syndrome or neurodegeneration.
Endogenous Toxins: Targets for Disease Treatment and Prevention is the very first resource to tie together all the current knowledge from many disciplines. Until now this has only been available from widely dispersed sources in the primary literature. The importance of this publication cannot be underestimated, with diet- and metabolism-related diseases having become a prime global health concern.
The authors, both of whom are leaders in the field, have designed a truly comprehensive one-stop reference for researchers and professionals in toxicology, pharmacology and medicine. They present the complete picture on what is currently known about endogenous toxins, including their generation, modes of action, resulting disease conditions, and available countermeasures.
Endogenous Toxins: Targets for Disease Treatment and Prevention will appeal to a broad group of toxicologists, biochemists, nutrition specialists and physiologists, as well as food scientists and the food industry.
Part 1 systematically covers important toxic molecule species, including metabolic intermediates and reactive oxygen species.
Part 2 discusses the role of genetically determined metabolic malfunctions, such as galactosemia, hyperlipidemia, porphyria, hemochromatosis and related conditions.
Part 3 discusses acquired and chronic diseases caused or exacerbated by endogenous toxins, such as hepatic injury, asthma, rheumatism, colorectal cancer, reperfusion diseases, neurodegeneration and aging.
Part 4 reviews current strategies to control and minimize the effect of endogenous toxins, either by nutritional or pharmacological interventions.